Danaher Corporation is a US life sciences and diagnostics conglomerate headquartered in Washington, D.C. Founded in 1984 and listed on the New York Stock Exchange under the ticker DHR, the company runs a group of science and technology businesses spanning biotechnology, life sciences, and diagnostics. It employs roughly 63,000 people (2024) across about 700 locations in some 50 countries.
The company is led by President and Chief Executive Officer Rainer M. Blair. Brothers Steven M. Rales and Mitchell P. Rales, who built the company through the Danaher Business System of acquisitions and continuous improvement, serve as Chairman of the Board and Chairman of the Executive Committee. Matthew Gugino became Chief Financial Officer effective February 28, 2026, succeeding Matt McGrew, who had held the role since January 2019.
Danaher reported revenue of about US$24.57 billion for fiscal 2025 and carried a market capitalization near US$125.8 billion as of July 2026. In India the company runs a development center in Bengaluru with over 300 software engineers supporting many of its operating companies, along with a commercial office in Mumbai. Its shares trade on the S&P 500 and NYSE.
Key People
Rainer M. Blair
President and Chief Executive Officer
Matthew Gugino
Chief Financial Officer
Steven M. Rales
Chairman of the Board
Mitchell P. Rales
Chairman of the Executive Committee
Interview process at Danaher
(125 interview reviews)
Interview experience
8/10
Interview difficulty
Medium
Interview process length
About a week
Overall experience
PoorExcellent
EasyDifficult
How long the process takes
About a day or two22%
About a week37%
About a month19%
More than one month21%
See all Danaher interview questions & answers
Browse question banks by role, round and company, with answers and examples.
Danaher Salaries in the US & India (Updated 2026)
Software Engineer (India)
Reported average
₹15,50,240/yr
3 salaries Salaries submitted
Senior Software Engineer (India)
Reported average
₹13,27,724/yr
3 salaries Salaries submitted
Staff Software Engineer
Reported average
$155,402/yr
4 salaries Salaries submitted
Software Engineer (US)
Reported average
$82,012/yr
2 salaries Salaries submitted
Commercial Sales Executive
Reported average
$254,560/yr
1 salary Salaries submitted
Sales Specialist
Reported average
$223,624/yr
1 salary Salaries submitted
Know your worth at Danaher
Compare offers, benchmark your role, and see what similar candidates earn.
Free guides to AI video screens, coding tests and how scoring works.
Benefits
Medical / health insurance
Dental insurance
Vision insurance
Employee Assistance Program (mental health support)
Health Savings Account (HSA)
401(k) retirement plan
Life insurance (1.5x base salary, up to $2M)
Disability insurance
Maternity leave (14 weeks)
Paternity leave (8 weeks)
Paid vacation (starts at two weeks)
Tuition reimbursement
Latest News & Updates
July 21, 2026
Danaher reports second quarter 2026 results
Danaher posted Q2 2026 revenue of $6.3 billion, up 5.5% year over year, with net earnings of $870 million ($1.23 diluted EPS) and adjusted diluted EPS of $1.94, up 8.0%. It raised full-year adjusted EPS guidance to $8.45 to $8.60, citing the earlier than expected close of the Masimo acquisition.
Danaher's Leica Biosystems agreed to acquire StatLab Medical Products, a maker of anatomical pathology consumables, from private equity owners. The deal is expected to close by the end of 2026, subject to regulatory approvals.
Danaher closed its acquisition of Masimo Corporation, a specialty diagnostics provider focused on pulse oximetry and patient monitoring for acute care settings. Masimo was subsequently delisted from Nasdaq.
Danaher reported Q1 2026 revenue of $6.0 billion, up 3.5% year over year, with net earnings of $1.0 billion, diluted EPS of $1.45, and adjusted diluted EPS of $2.06, up 9.5%. Growth was led by biotechnology, offset by softer diagnostics.
Danaher entered a definitive agreement to acquire Masimo at $180.00 per share in cash, a total enterprise value of about $9.9 billion, expanding its diagnostics and patient monitoring portfolio ahead of the June 2026 close.